Loading…
Organogenesis Holdings Inc. is projected to decline to $2.63 by 2027, a -1% move from its current price of $2.66. ORGO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.57 | $2.66 | $2.75 | +0.01% |
| May 30 | $2.54 | $2.66 | $2.79 | +0.03% |
| May 31 | $2.51 | $2.66 | $2.82 | +0.04% |
| Jun 1 | $2.49 | $2.66 | $2.85 | +0.05% |
| Jun 2 | $2.47 | $2.66 | $2.87 | +0.06% |
| Jun 3 | $2.45 | $2.66 | $2.89 | +0.08% |
| Jun 4 | $2.44 | $2.66 | $2.91 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.44 | $2.66 | $2.91 | +0.09% |
| Week 2 | $2.35 | $2.66 | $3.02 | +0.18% |
| Week 3 | $2.29 | $2.67 | $3.11 | +0.27% |
| Week 4 | $2.24 | $2.67 | $3.19 | +0.36% |
| Week 5 | $2.19 | $2.67 | $3.26 | +0.45% |
| Week 6 | $2.15 | $2.67 | $3.32 | +0.54% |
| Week 7 | $2.12 | $2.68 | $3.38 | +0.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Organogenesis Holdings Inc. is a healthcare company focused on regenerative medicine and advanced wound care. It develops, manufactures, and commercializes products for the American market across the advanced wound care, surgical, and sports medicine sectors.
The company lists a broad portfolio of placental tissue grafts and wound care products designed to protect wounds and support healing, including Affinity, Novachor, Apligraf, Dermagraft, NuShield, PuraPly AM and SX, PuraPly MZ, PuraForce, FortiShield, TransCyte, ReNu, CYGNUS Dual, VIA Matrix, SimpliMax, and other placental products.
Organogenesis is headquartered in Canton, Massachusetts, and serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. The description emphasizes its portfolio across regenerative and wound-care solutions and its ongoing development programs.
Organogenesis Holdings Inc. (ORGO) is currently priced at $2.66 per share, with a market capitalization of $342.27M and a ranking of 3390. The stock’s near-term trajectory is informed by a multi-year forecast that shows a path from a neutral early-year outlook to stronger gains later in the decade.
Forecasts project a gradual rise in average price through 2030, with meaningful upside by 2040 and 2050. The 2030 average is $2.93, the 2040 average is $6.05, and the 2050 average is $10.41, with corresponding ROIs of 10.2%, 127.5%, and 291.2% respectively. The sentiment shifts from neutral in the near term to bullish in the later years.
A major floor 19.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 59.0% above — clearing it would confirm fresh momentum.
Key ORGO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORGO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.64 | Buy | $2.63 | Buy |
| MA 10 | $2.58 | Buy | $2.58 | Buy |
| MA 20 | $2.52 | Buy | $2.54 | Buy |
| MA 50 | $2.44 | Buy | $2.64 | Buy |
| MA 100 | $3.07 | Sell | $3.04 | Sell |
| MA 200 | $3.94 | Sell | $3.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.71 | Neutral |
| Stoch RSI (14) | 83.08 | Sell |
| CCI (20) | 88.33 | Neutral |
| Williams %R (14) | -10.81 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 12.24 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 89.19 | Sell |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 0.16 | Buy |
| Ultimate (7,14,28) | 71.95 | Sell |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 2.71 | Sell |
| ADX (14) | 14.16 | Neutral |
| ATR (14) | 0.07 | Info |
In the next 30 days, the technical picture remains bullish overall. The RSI14 sits at 60, while the 50-day simple moving average is $2.44 and the 200-day simple moving average is $3.96. Key near-term levels include support at $2.30 and resistance at $2.70, framing a 30-day trading range of $2.10 to $3.36.
The stock’s current price of $2.66 sits between the short-term SMA signals, signaling a cautious upward bias with limited downside risk if the $2.30 support holds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.24 | $2.66 | $3.47 | 0% | Neutral | |
| $2.04 | $2.63 | $3.62 | -1% | Neutral | |
| $1.95 | $2.60 | $3.72 | -2% | Neutral | |
| $2.06 | $2.83 | $4.20 | +6% | Neutral | |
| $2.12 | $2.98 | $4.55 | +12% | Neutral | |
| $2.44 | $3.52 | $5.50 | +32% | Bullish | |
| $2.77 | $4.08 | $6.52 | +53% | Bullish | |
| $2.62 | $3.94 | $6.43 | +48% | Bullish | |
| $2.61 | $4.01 | $6.66 | +51% | Bullish | |
| $2.58 | $4.04 | $6.83 | +52% | Bullish | |
| $3.59 | $6.13 | $11.11 | +131% | Bullish | |
| $5.38 | $10.77 | $21.61 | +305% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.24 | $2.66 | $3.12 | +0.00% |
| June 2026 | $2.21 | $2.60 | $3.16 | -2.09% |
| July 2026 | $2.26 | $2.69 | $3.32 | +3.35% |
| August 2026 | $2.30 | $2.77 | $3.46 | +2.93% |
| September 2026 | $2.24 | $2.71 | $3.42 | -2.07% |
| October 2026 | $2.21 | $2.69 | $3.42 | -0.98% |
| November 2026 | $2.24 | $2.74 | $3.51 | +2.00% |
| December 2026 | $2.18 | $2.68 | $3.47 | -2.06% |
Click any year to see its month-by-month ORGO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Organogenesis Holdings Inc.'s 2026 outlook centres on $2.66, within a $2.24 to $3.47 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORGO could reach as high as $3.62, with a base case around $2.63 and support toward $2.04 — roughly -1% from $2.66. A consolidation phase looks the most probable path here.
Expect ORGO to range from $1.95 to $3.72 through 2028. The $2.60 average target implies a -2% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The ORGO price prediction for 2029 points to an average of $2.83 (low $2.06, high $4.20) — a potential gain of +6% on today's $2.66. A consolidation phase looks the most probable path here.
In 2030, ORGO is projected to trade between $2.12 and $4.55, averaging $2.98 — a potential gain of +12% from today's $2.66. That is up +5% on the projected 2029 average. Price action looks broadly range-bound.
Organogenesis Holdings Inc.'s 2031 outlook centres on $3.52, within a $2.44 to $5.50 range. That is up +18% on the projected 2030 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORGO could reach as high as $6.52, with a base case around $4.08 and support toward $2.77 — roughly +53% from $2.66. Momentum favours further upside here.
Expect ORGO to range from $2.62 to $6.43 through 2033. The $3.94 average target implies a +48% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORGO price prediction for 2034 points to an average of $4.01 (low $2.61, high $6.66) — a potential gain of +51% on today's $2.66. Momentum favours further upside here.
In 2035, ORGO is projected to trade between $2.58 and $6.83, averaging $4.04 — a potential gain of +52% from today's $2.66. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Organogenesis Holdings Inc.'s 2040 outlook centres on $6.13, within a $3.59 to $11.11 range. That is up +52% on the projected 2035 average. That marks a +131% change versus current levels. Momentum favours further upside here.
By 2050, ORGO could reach as high as $21.61, with a base case around $10.77 and support toward $5.38 — roughly +305% from $2.66. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORGO today (≈ 375.93985 ORGO) could be worth
$4,049.07
+$3,049.07 (+305%) by 2050 · US Dollar
Based on the average projected ORGO price of $10.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORGOwould be worth at today's price.
$1,000 invested in ORGO on May 27, 2025 (≈ 336.700333 ORGO) would be worth
$895.62
-$104.38 (-10.4%) today · 0.90× · US Dollar
Based on a ORGO entry price of $2.97 vs. today's $2.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.55 | $1,043.14 | +4.3% |
| 1 month ago | $2.39 | $1,112.97 | +11.3% |
| 3 months ago | $3.7 | $718.92 | -28.1% |
| 6 months ago | $5.18 | $513.51 | -48.6% |
| 1 year ago | $2.97 | $895.62 | -10.4% |
| All time (5.0y) ago | $18.15 | $146.56 | -85.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORGO forecast.
Our base-case forecast reaches $5.30 around 2040.
Implied market cap at $5.30: $681.98M
The multi-year forecast points to a rising price trajectory with notable strength into the 2030s and beyond. In 2030, the average forecast price is $2.93 with a 10.2% ROI, suggesting modest gains from the current level. By 2040, the average rises to $6.05, with a substantial 127.5% ROI, indicating stronger long-term upside.
By 2050, the average is $10.41, with a 291.2% ROI, signaling a pronounced long-term appreciation. The outlook becomes bullish from 2031 onward, with higher average prices and expanding upside potential through the decade and into 2050.
Risks include near-term variability, as some earlier years show flat or negative ROI (e.g., 2027 with -1.9% and 2028 with -3.1%), before resuming an upward trajectory in subsequent years. Overall, the forecast landscape suggests meaningful upside in the long run, but these are estimates and not guarantees, varying with market conditions and fundamentals.
Tap a question to reveal the answer.
Avg $2.93; min $2.05; max $4.54; ROI 10.2%; sentiment Neutral.
Long-term projections show bullish sentiment beginning in 2031, with 2040 avg $6.05 (ROI 127.5%) and 2050 avg $10.41 (ROI 291.2%), indicating meaningful upside over time, but near-term variability exists.
Yes. The 2050 forecast lists an average of $10.41 with a max of $21.44 and a bullish sentiment, corresponding to a 291.2% ROI.
The stock has RSI 60 with SMA50 at $2.44 and SMA200 at $3.96. It shows support at $2.30 and resistance at $2.70, within a 30-day range of $2.10 to $3.36, suggesting a near-term bullish bias but with defined risk levels.
2026: min $2.24, avg $2.66, max $3.45 (neutral); 2027: min $2.01, avg $2.61, max $3.63 (neutral); 2028: min $1.91, avg $2.58, max $3.74 (neutral); 2029: min $1.99, avg $2.76, max $4.16 (neutral to modestly bullish).
Organogenesis Holdings Inc. Community Discussion
0Share your Organogenesis Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.